Business
Harrow Health to Announce Third Quarter 2019 Financial Results on November 13, 2019
NASHVILLE, Tenn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Wednesday, November
About this update from Harrow, Inc.
[{"type":"text","content":"NASHVILLE, Tenn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Wednesday, November 13, 2019, it will release third quarter 2019 financial results and host a conference call at 5:00 p.m. Eastern Standard Time / 2:00 p.m. Pacific Standard Time to discuss the financial results and recent business developments.\n After the close of the market on November 13, 2019, Harrow will issue a press release containing relevant financial results and a link to a Letter to Shareholders. Going forward, each Letter to Shareholders will be archived on the Harrow Investor Relations website in the Archives section, which can be found by clicking here. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction and overview of the quarter and outlook for the business. Conference Call Details: U.S. callers: (844) 602-0380International callers: (862) 298-0970Audio-only webcast: please click here Conference Call Replay: A dial in replay of the call will be available until December 13, 2019. The webcast replay will be available until February 13, 2020. U.S. callers: (877) 481-4010, Replay ID: 55904International callers: (919) 882-2331, Replay ID: 55904Webcast: please click here About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, Stowe Pharmaceuticals and Radley Pharmaceuticals, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this ...